Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04568811
Recruitment Status : Active, not recruiting
First Posted : September 29, 2020
Last Update Posted : February 10, 2021
Sponsor:
Information provided by (Responsible Party):
Jiangsu Province Centers for Disease Control and Prevention

Brief Summary:

The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China. It has manifest into a global health crisis with escalating confirmed cases and spread across many countries.

In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of diseases caused by COVID-19 can be tough for current treatment.

This study is a phase I clinical trial of booster vaccination of adenovirus type-5 vectored COVID-19 vaccine 6 months after prime vaccination. The investigators intent to evaluate the safety and immunogenicity of booster vaccination of adenovirus type-5 vectored COVID-19 vaccine in healthy adults aged aged 18-60 years.


Condition or disease Intervention/treatment Phase
Adenovirus Type-5 Vectored COVID-19 Vaccine Biological: Adenovirus Type-5 Vectored COVID-19 Vaccine Phase 1

Detailed Description:

The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China. It has manifest into a global health crisis with escalating confirmed cases and spread across many countries.

In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of diseases caused by COVID-19 can be tough for current treatment.

This is a single-center, open-label phase I clinical trial of booster vaccination in healthy 18 to 60 years of age, inclusive, who has been prime vaccinated with adenovirus type-5 vectored COVID-19 vaccine. This clinical trial is designed to assess the safety and immunogenicity of booted vaccination of adenovirus type-5 vectored COVID-19 vaccine manufactured by Beijing Institute of Biotechnology and CanSino Biologics Inc.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 89 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years
Actual Study Start Date : September 26, 2020
Actual Primary Completion Date : October 25, 2020
Estimated Study Completion Date : September 27, 2021

Arm Intervention/treatment
Experimental: Adenovirus Type-5 Vectored COVID-19 Vaccine Biological: Adenovirus Type-5 Vectored COVID-19 Vaccine
Low dose adenovirus type-5 vectored COVID-19 vaccine (5E10 vp)




Primary Outcome Measures :
  1. Occurrence of adverse reactions within 14 days after booster vaccination [ Time Frame: 0-14 days post-vaccination ]
    Occurrence of adverse reactions within 14 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine


Secondary Outcome Measures :
  1. Occurrence of adverse events within 14 days after booster vaccination [ Time Frame: 0-14 days post-vaccination ]
    Occurrence of adverse events within 14 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine

  2. Occurrence of adverse events within 28 days after booster vaccination [ Time Frame: 0-28 days post-vaccination ]
    Occurrence of adverse events within 28 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine

  3. Occurrence of serious adverse events within 28 days after booster vaccination [ Time Frame: 0-28 days post-vaccination ]
    Occurrence of serious adverse events within 28 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine

  4. Occurrence of serious adverse events within 6 months after booster vaccination [ Time Frame: 6 months post-vaccination ]
    Occurrence of serious adverse events within 6 months after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine

  5. Occurrence of serious adverse events within 12 months after booster vaccination [ Time Frame: 12 months post-vaccination ]
    Occurrence of serious adverse events within 12 months after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine

  6. Changes in laboratory test indicators before and 1 day after vaccination [ Time Frame: 1 day post-vaccination ]
    Changes in laboratory test indicators (including white blood cell count, lymphocyte count, neutrophils, platelets, hemoglobin, ALT, AST, total bilirubin, fasting blood glucose, creatinine) before and 1 day after vaccination

  7. Antibody of S-RBD at day 14, day 28, month 6 and month 12 after booster vaccination [ Time Frame: 14 days, 28 days, 6 months and 12 months post-vaccination ]
    Antibody of S-RBD at day 14, day 28, month 6 and month 12 after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine

  8. Cellular immunity at day 14 after booster vaccination [ Time Frame: 14 days post-vaccination ]
    Cellular immunity at day 14 after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants who has received prime vaccination of adenovirus type-5 vectored COVID-19 vaccine
  • Able to understand the content of informed consent and willing to sign the informed consent
  • Negative in HIV diagnostic test.
  • Axillary temperature ≤37.0°C.
  • General good health as established by medical history and physical examination.
  • Able to complete 12 months visit

Exclusion Criteria:

  • Family history of seizure, epilepsy, brain or mental disease
  • Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past.
  • Woman who is pregnant, breast-feeding on day of enrollment, or become pregnant during the next 12 months
  • Any acute fever disease or infections.
  • History of SARS
  • Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease.
  • Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc.
  • Hereditary angioneurotic edema or acquired angioneurotic edema
  • Urticaria in last one year
  • No spleen or functional spleen.
  • Platelet disorder or other bleeding disorder may cause injection contraindication
  • Faint at the sight of needles.
  • Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months.
  • Prior administration of blood products in last 4 months
  • Prior administration of other research medicines in last 1 month
  • Prior administration of attenuated vaccine in last 1 month
  • Prior administration of inactivated vaccine in last 14 days
  • Current anti-tuberculosis prophylaxis or therapy
  • According to the judgement of investigator,various medical, psychological, social or other conditions, those could affect the subjects to sign informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04568811


Locations
Layout table for location information
China, Hubei
A rehabilitation centre in Wuhan
Wuhan, Hubei, China
Sponsors and Collaborators
Jiangsu Province Centers for Disease Control and Prevention
Layout table for additonal information
Responsible Party: Jiangsu Province Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT04568811    
Other Study ID Numbers: JSVCT100
First Posted: September 29, 2020    Key Record Dates
Last Update Posted: February 10, 2021
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Adenoviridae Infections
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
DNA Virus Infections